4 news items
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
ADAP
17 Jun 24
: Adaptimmune's mission is to transform cancer treatment by engineering naturally-occurring TCRs to better recognize and bind to specific cancer
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
ABEO
ADAP
INBS
31 May 24
degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
. Combining uza-cel with Galapagos' unique decentralized manufacturing platform is a natural synergy and has the potential to deliver an even more
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
decentralized manufacturing platform is a natural synergy and has the potential to deliver an even more effective TCRÂ T-cell therapy for people
- Prev
- 1
- Next